Isn't anyone here watching Supergen?
I've been checking it out, like its business plan, and had decided to get some
on the next market dip ---and so missed the latest boat.
Thursday, SUPG closed at 8 5/8.
Friday morning they issued a press release -- filed an SNDA to extend Nipent
to a wide variety of lymphomas, including CTCL and PTCL.
Friday the 26th, Supg closed at 9 3/4
Today it closed at 10 5/8.
Both days the volume was up, but still relatively light.
Will it drift back down so I can get in?
(The general market looks volatile and toppy to me.)
----------------
As usual, Rubinfeld was flamboyant, and provocative.
Without naming names, the release specifically challenged Ligand and Ontak
for the CTCL market
-- and mentioned that Nipent has received Orphan Drug designation for CTCL.
Without giving any details, the press release mentioned a couple of Nipent trials involving 191 CTCL patients at SWOG and at a European site
-- and claimed that "Most investigators describe the treatment as being well tolerated, with low bone marrow toxicity."
(Nipent does have a long track record
-- but its monograph in RXmed looks pretty harsh to me.
rxmed.com )
I looked, but could find nothing relevant at Southwest Oncology Group's website.
swog.saci.org or oo.saci.org
Can any of you find information about these trials?
2/26/99 press release - supergen.com
I'd appreciate comments, insights from the regulars.
Regards,
Cheryl |
